NEUROLEPTIC MALIGNANT SYNDROME-LIKE STATE FOLLOWING A WITHDRAWAL OF ANTIPARKINSONIAN DRUGSTORU M; MATSUDA O; MAKIGUCHI K et al.1981; J. NERV. MENT. DIS.; ISSN 0022-3018; USA; DA. 1981; VOL. 169; NO 5; PP. 324-327; BIBL. 12 REF.Article

UTILIZATION OF ANTIPARKINSON DRUGS IN NORWAY, SWEDEN, DENMARK AND FINLAND 1975-1979AQUILONIUS SM; GRANAT M; HARTVIG P et al.1981; ACTA NEUROL. SCAND.; ISSN 0001-6314; DNK; DA. 1981; VOL. 64; NO 1; PP. 47-53; BIBL. 7 REF.Article

A DRUG INFORMATION NOTE FOR PATIENTS RECEIVING ANTIPARKINSONIAN AGENTSSHEN WW.1981; HOSP. COMMUNITY PSYCHIATRY; ISSN 0022-1597; USA; DA. 1981; VOL. 32; NO 8; PP. 575; BIBL. 10 REF.Article

LE TRAITEMENT ACTUEL DE LA MALADIE DE PARKINSONDELWAIDE PJ.1981; LOUV. MED.; ISSN 0024-6956; BEL; DA. 1981; VOL. 100; NO 6; PP. 381-387; ABS. ENG; BIBL. 3 REF.Article

BROMOCRIPTINE AND LISURIDE IN PARKINSON DISEASELIEBERMAN AN; GOVINDAN GOPINATHAN; NEOPHYTIDES A et al.1983; ANNALS OF NEUROLOGY; ISSN 0364-5134; USA; DA. 1983; VOL. 13; NO 1; PP. 44-47; BIBL. 16 REF.Article

RECENT ADVANCES IN THE TREATMENT OF PARKINSON'S DISEASE: THE ROLE OF BROMOCRIPTINELE WITT PA; CALNE DB.1981; J. NEURAL TRANSM.; ISSN 0300-9564; AUT; DA. 1981; VOL. 51; NO 1-2; PP. 175-184; BIBL. 2 P.Article

BROMOCRIPTINE: LOW-DOSE THERAPY IN PARKINSON DISEASETEYCHENNE PF; BERGSRUD D; RACY A et al.1982; NEUROLOGY; ISSN 0028-3878; USA; DA. 1982; VOL. 32; NO 6; PP. 577-583; BIBL. 25 REF.Article

SENILE PARKINSONISM, A SURVEY OF CURRENT TREATMENTWHITE NJ; BARNES TRE.1981; AGE & AGEING; ISSN 0002-0729; GBR; DA. 1981; VOL. 10; NO 2; PP. 81-86; BIBL. 11 REF.Article

INTERESSE CLINICO DEL TEST ELETTRORETINOGRAFICO NEL MORBO DI PARKINSON = INTERET CLINIQUE DU TEST ELECTRORETINOGRAPHIQUE DANS LA MALADIE DE PARKINSONCAVALLACCI G; PEROSSINI M.1980; MINERVA OFTALMOL.; ITA; DA. 1980; VOL. 22; NO 1; PP. 1-5; ABS. ENG; BIBL. 17 REF.Article

THE EFFECT OF BROMOCRIPTINE (BCT) ON THE ON-OFF PHENOMENONGLANTZ R; GOETZ CG; NAUSIEDA PA et al.1981; J. NEURAL TRANSM.; ISSN 0300-9564; AUT; DA. 1981; VOL. 52; NO 1-2; PP. 41-47; BIBL. 14 REF.Article

MORTALITAET BEIM PARKINSONSYNDROM UND IHRE BEEINFLUSSUNG DURCH L-DOPA = MORTALITE AU COURS DE LA MALADIE DE PARKINSON. INFLUENCE DE LA L-DOPASCHNEIDER E; FISCHER PA; JACOBI P et al.1981; FORTSCHR. NEUROL. PSYCHIATR. IHRER GRENZGEB.; ISSN 0015-8194; DEU; DA. 1981; VOL. 49; NO 5; PP. 187-192; ABS. ENG; BIBL. 29 REF.Article

THERAPEUTIC ANTAGONISM BETWEEN ANTICHOLINERGIC ANTIPARKINSONISM AGENTS AND NEUROLEPTICS IN SCHIZOPHRENIA: IMPLICATIONS FOR A NEUROPHARMACOLOGICAL MODELMAN MOHAN SINGH; KAY SR.1979; NEUROPSYCHOBIOLOGY; CHE; DA. 1979; VOL. 5; NO 2; PP. 74-86; BIBL. 2 P.Article

DRUG-INDUCED ASTERIXIS IN PARKINSON DISEASEGLANTZ R; WEINER WJ; GOETZ CG et al.1982; NEUROLOGY; ISSN 0028-3878; USA; DA. 1982; VOL. 32; NO 5; PP. 553-555; BIBL. 13 REF.Article

IMPROVED CONTROL OF BRITTLE PARKINSONISM BY SEPARATE ADMINISTRATION OF LEVODOPA AND BENSERAZIDEMCLELLAN DL; DEAN BC.1982; BR. MED. J.; ISSN 0007-1447; GBR; DA. 1982; VOL. 284; NO 6321; PP. 1001-1002Article

PARKINSON'S DISEASE CONCEPTS AND PROSPECTS. SYMPOSIUM. PROCEEDINGS; GRONINGEN; 1977.1977; EXCERPTA MED., INTERNATION, CONGR. SER.; PAYS-BAS; DA. 1977; NO 429; PP. 1-121; BIBL. DISSEM.Conference Paper

DOSAGE FLUORIMETRIQUE DU CHLORHYDRATE DE TRIHEXYPHENIDYLE ET DE QUELQUES DERIVES DE STRUCTURE ANALOGUE.GELBCKE M.1976; J. PHARM. BELG.; BELG.; DA. 1976; VOL. 31; NO 4; PP. 397-402; ABS. ANGL. NEERL.; BIBL. 17 REF.Article

THE EFFECTS OF PERGOLIDE ON THE CARDIOVASCULAR SYSTEM OF 40 PATIENTS WITH PARKINSON'S DISEASELEIBOWITZ M; LIEBERMAN AN; NEOPHYTIDES A et al.1983; ADVANCES IN NEUROLOGY; ISSN 0091-3952; USA; DA. 1983; VOL. 37; PP. 121-130; BIBL. 24 REF.Article

A 6-MONTH TRIAL OF PERGOLIDE MESYLATE ON THE TREATMENT OF IDIOPATHIC PARKINSON'S DISEASEKLAWANS HL; TANNER CM; GLATT S et al.1983; ADVANCES IN NEUROLOGY; ISSN 0091-3952; USA; DA. 1983; VOL. 37; PP. 75-83; BIBL. 29 REF.Article

L-DOPA TREATMENT OF PARKINSON'S DISEASE: A TEN-YEAR FOLLOW-UP STUDYBAUER RB; STEVENS C; REVENO WS et al.1982; J. AM. GERIATR. SOC.; ISSN 0002-8614; USA; DA. 1982; VOL. 30; NO 5; PP. 322-325; BIBL. 14 REF.Article

CARDIAC EFFECTS OF PERGOLIDELEIBOWITZ M; LIEBERMAN A; GOLDSTEIN M et al.1981; CLIN. PHARMACOL. THER.; ISSN 0009-9236; USA; DA. 1981; VOL. 30; NO 6; PP. 718-723; BIBL. 25 REF.Article

LISURIDE IN THE TREATMENT OF PARKINSONISMSCHACHTER M; SHEEHY MP; PARKES JD et al.1980; ACTA NEUROL. SCAND.; ISSN 0001-6314; DNK; DA. 1980; VOL. 62; NO 6; PP. 382-385; BIBL. 5 REF.Article

MOYENS THERAPEUTIQUES ET INDICATIONS DU TRAITEMENT MEDICAL DE LA MALADIE DE PARKINSONALLAIN H; VAN DEN DRIESSCHE J; MENAULT F et al.1980; SEM. HOP.; FRA; DA. 1980; VOL. 56; NO 5-6; PP. 277-282; ABS. ENG; BIBL. 7 REF.Article

REVERSIBLE HAEMOLYTIC ANAEMIA AFTER LEVODOPA-CARBIDOPABERNSTEIN R.1979; BRIT. MED. J.; GBR; DA. 1979; NO 6176; PP. 1461-1462; BIBL. 4 REF.Article

SUR QUELQUES SEVRAGES DANGEREUX EN NEUROLOGIELAPLANE D.1979; REV. PRATICIEN; FRA; DA. 1979; VOL. 19; NO 1; PP. 65-68; ABS. ENG; BIBL. 2 REF.Article

ANTIPARKINSONICS, NEUROLEPTICS, AND TARDIVE DYSKINESIAMALLYA A; JOSE C; BAIG M et al.1979; BIOL. PSYCHIATRY; USA; DA. 1979; VOL. 14; NO 4; PP. 645-649; BIBL. 13 REF.Article